主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
ASND
#7008
Ascendis Pharma A/S American Depositary Shares
233.500
0
+5.33%
版块:
基础:
利润货币:
日范围
年范围
日变化
+5.33%
每月变动
-2.17%
6个月变化
+13.86%
年变化
+13.86%
前一天收盘价
221.690
0
Open
233.660
0
Bid
Ask
Low
233.500
0
High
233.660
0
交易量
47
市场
股票
医疗保健
ASND
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
Q4, 25
TTM
Key stats
Total common shares outstanding
60.69 M
61.98 M
237.53 M
Valuation ratios
Enterprise value
8.36 B
13.22 B
35.83 B
Price to earnings ratio
—
—
—
Price to sales ratio
—
—
—
Price to cash flow ratio
—
—
—
Price to book ratio
—
—
—
Enterprise value to EBITDA ratio
—
—
—
Profitability ratios
Return on assets %
—
—
—
Return on equity %
—
—
—
Return on invested capital %
—
—
—
Gross margin %
—
—
—
Operating margin %
—
—
—
EBITDA margin %
—
—
—
Net margin %
—
—
—
Liquidity ratios
Quick ratio
—
—
—
Current ratio
—
—
—
Inventory turnover
—
—
—
Asset turnover
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
Debt to equity ratio
—
—
—
Long term debt to total assets ratio
—
—
—
Long term debt to total equity ratio
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
EBIT per share
—
—
—
EBITDA per share
—
—
—
Total debt per share
—
—
—
Cash per share
—
—
—
Net current asset value per share
—
—
—
Tangible book value per share
—
—
—
Working capital per share
—
—
—
Book value per share
—
—
—
新闻
FDA批准Ascendis每周一次的软骨发育不全症治疗药物
FDA approves Ascendis’ once-weekly achondroplasia treatment
Ascendis Pharma安排年度股东大会并发布2025年报告
Ascendis Pharma schedules annual meeting and releases 2025 reports
RBC Capital重申Ascendis Pharma评级,看好Yorvipath增长势头
RBC Capital reiterates Ascendis Pharma stock rating on Yorvipath momentum
Cantor Fitzgerald上调Ascendis Pharma目标价至300美元,看好CNP产品线前景
Cantor Fitzgerald raises Ascendis Pharma stock price target to $300 on CNP franchise outlook
Stifel上调Ascendis Pharma目标价至325美元,看好Yorvipath增长
Stifel raises Ascendis Pharma stock price target to $325 on Yorvipath growth
Baird maintains BioMarin stock rating amid competitor’s positive trial data
BioMarin和Ascendis股价因BridgeBio强劲的软骨发育不全数据而下跌